---
title: Clinical Utility of MyPath Melanoma
image: https://info.castlebiosciences.com/hubfs/CM-1.png
---

![MyPath-Melanoma-RGB](https://info.castlebiosciences.com/hs-fs/hubfs/MyPath/MyPath-Melanoma-RGB.jpg?width=139&height=62&name=MyPath-Melanoma-RGB.jpg "MyPath-Melanoma-RGB")

# Clinical utility of MyPath Melanoma in the dermatology practice

MyPath Melanoma is a 23-gene expression profile test that provides objective information to aid in the diagnosis and treatment decision making of challenging melanocytic lesions, as well as when melanoma cannot be ruled out. 

[Order test](https://castlebiosciences.com/Utilities/order-a-test)

1. Diagnostic support in challenging histopathologic scenarios

MyPath Melanoma is particularly useful in equivocal cases involving dermoscopic concern and the following histopathologic findings:

- Moderate to severely dysplastic nevi
- Atypical intraepidermal melanocytic proliferations (AIMPs)
- Atypical junctional melanocytic proliferations (AJMPs)
- Cases where melanoma cannot be definitively ruled out
- Pathology reports with non-definitive language such as “unusual features” or “suspicious for melanoma in situ (MIS)”

2. Clinical decision-making in cases of dermoscopy-pathology discordance

When dermoscopic findings raise concern but histopathology is inconclusive, MyPath Melanoma can support a more objective and individualized treatment plan:

**Malignant MyPath Melanoma Result**: Consider an  excision with a 5mm surgical margin when the result is suggestive of malignancy.

 

3. Management of ambiguous lesions in cosmetically sensitive areas

MyPath Melanoma has a high negative predictive value (NPV) and is particularly valuable when managing melanocytic lesions in cosmetically sensitive regions (e.g., the face, ears ):

- **Benign MyPath Melanoma Result:** Consider deferring further surgical intervention and instead monitor the biopsy scar site with longitudinal digital dermoscopy imaging.  At follow-up, if dermoscopic changes are observed (e.g., new pigmentation, round structures, blue-white veil, or other concerning features), consider re-excision with a 5mm margin.

![Screenshot 2025-09-18 204909](https://info.castlebiosciences.com/hubfs/Screenshot%202025-09-18%20204909.png "Screenshot 2025-09-18 204909")

Surgical management example from an ACMS-trained Mohs Surgeon

![Screenshot 2026-01-27 090809](https://info.castlebiosciences.com/hubfs/Screenshot%202026-01-27%20090809.png "Screenshot 2026-01-27 090809")

[![mypath-cta-1](https://info.castlebiosciences.com/hubfs/mypath-cta-1.png "mypath-cta-1")](https://castlebiosciences.com/mypath-dermjourney)